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Abstract
Background: Sarcosine has been investigated as a prostate cancer biomarker with mixed results concerning its
predictive power. We performed a case–control evaluation of the predictive value of serum sarcosine for early
detection in a population-based cohort of men undergoing prostate-specific antigen (PSA) screening.
Methods: For analysis we used 251 cancer cases and 246 age-matched non-cancer cases from the San Antonio
Biomarkers Of Risk (SABOR) screening study. For cancer cases, pre-diagnostic serum was utilized for sarcosine
measurement. Controls were defined as men who had been followed at least for 5 years on study with no
prostate cancer diagnosis; sarcosine was measured on the initial baseline serum. HPLC-electrospray ionization
mass spectrometry was used for serum sarcosine quantification. The association of sarcosine with prostate cancer
was assessed using area underneath the receiver-operating characteristic curve (AUC), and logistic regression
adjusting for PSA, digital rectal exam, family history, age, race, and history of a prior negative biopsy. Among
cancer cases, nominal logistic regression was used for the association of sarcosine with Gleason grade.
Results: Sarcosine levels were overlapping between the prostate cancer cases (median 15.8 uM, range 6.2 to 42.5 uM)
and controls (median 16.2 uM, range 6.4 to 53.6 uM). The AUC of sarcosine was not statistically different from random
chance either for participants with any PSA value (52.2 %) or those with PSA values in the range of 2 to 10 ng/mL
(54.3 %). Sarcosine was not predictive of Gleason score and added no independent predictive power to standard
prostate cancer risk factors for detection of prostate cancer (all p-values > 0.05).
Conclusions: Serum sarcosine should not be pursued further as a marker for the early detection of prostate cancer.
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Background
Metabolic profiling has identified sarcosine as a differential
metabolite in the development and progression of prostate
cancer [1]. Sarcosine, also known as N-methyglycine, is an
N-methyl derivate of the amino acid glycine synthesized by
glycine-N-methyltransferase (GNMT). GNMT has been
implicated in methylation and prostate cancer [2]. This link
led to interest in sarcosine as a prostate cancer biomarker.
In the few prior studies investigating sarcosine as a bio-
marker of prostate cancer, results have been conflicting;
some indicated higher risk associated with higher levels of
sarcosine and others, a lower risk [3, 4]. The methodology
of these studies has been either unclear or suboptimal, for
instance by using serum samples far in advance of the time
of biopsy. In order to definitively assess the potential of
serum sarcosine for further study, we evaluated its operat-
ing characteristics and independent predictive value in a
prospectively collected cohort of men, specifically assem-
bled for the evaluation of prostate cancer biomarkers.
Methods
Serum samples were obtained spanning the years from
2001 to 2009 from men enrolled in a prospective cohort
undergoing annual prostate-specific antigen (PSA) testing
as part of the San Antonio Biomarkers Of Risk (SABOR)
clinical validation site for the US National Cancer Institute
Early Detection Research Network (EDRN). The study
protocol and written consent procedures were approved by
the institutional review board at the University of Texas
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Health Science Center at San Antonio (UTHSCSA).
Cases, controls, serum samples, and risk measures were
selected as previously described [5]. Serum specimens
were collected within 2.5 years prior to the prostate cancer
diagnosis for cases and at the first baseline visit for con-
trols; the majority of specimens (92.7 %) were within
1 year. Controls included cancer-free men with a mini-
mum of 5 years follow-up after serum collection, a group
selected to minimize the risk of assigning as a control a
subject who harbored a tumor that would be discovered
within the intermediate term. The risk factors measured
included PSA (measured from the same serum sample as
used for sarcosine), digital rectal exam (DRE, result used
from the same patient visit as that for serum measurement
of PSA), age, race, family history of prostate cancer in a
first-degree relative, and history of a prior negative biopsy.
Serum sarcosine was measured using the UTHSCSA and
Cancer Center Mass Spectrometry Core Facility. Serum
(20 μl) was combined with stable isotope labeled internal
standard [2H3] sarcosine (25 μM, 40 μl), water (40 μl), and
sodium tetraborate solution (0.1 M, 50 μl) prior to deriv-
atization with 5-(dimethylamino) naphthalene-1-sulfonyl
chloride (dansyl chloride; 20 mM, 100 μl) at room
temperature for 30 min. After evaporation to dryness
by vacuum centrifugation, the derivatized samples were
dissolved in 200 μl of mobile phase A and transferred to
autosampler vials for HPLC-ESI-MS analysis on a Thermo
Fisher Q Exactive mass spectrometer used in conjunction
with a Thermo Fisher/Dionex Ultimate 3000 HPLC. Peak
areas were determined by processing through Quan
Browser (Thermo Fisher) and compared to calibration
curves that were generated by analysis of authentic
standards.
Risk factors and serum sarcosine levels were compared
between cases and controls using the chi-square test for
categorical outcomes and Wilcoxon test for continuous
measures. The AUC was computed for sarcosine and
tested using the Wilcoxon rank test for all cases and con-
trols, and in addition restricted to the group of cases and
controls with PSA in the 2 to 10 ng/mL range. Logistic
regression was used to assess the independent predictive
power of sarcosine to PSA, DRE, age, race, history of a
prior negative biopsy, and family history of prostate
cancer. Among prostate cancer cases, multinomial logistic
regression was used to assess whether sarcosine was asso-
ciated with the trivariate outcome of no cancer, low-grade
cancer (Gleason score < 7), and high-grade cancer.
Results
Characteristics of the 251 prostate cancer cases and 246
controls participating in the SABOR screening study are
shown in Table 1. Participants diagnosed with prostate
cancer were more likely to be of other races than
Caucasian, have an abnormal DRE, have a positive
family history of prostate cancer, and have a higher
PSA value (all p < 0.05). Controls had similar ages and
history of prior negative biopsy to the cancer cases.
Sarcosine levels were overlapping between the prostate
cancer cases (median 15.8 uM, range 6.2 to 42.5 uM) and
controls (median 16.2 uM, range 6.4 to 53.6 uM); see Fig. 1
and Table 1. The AUC of sarcosine was not statistically
different from random chance either for participants with
any PSA value (52.2 %) or those with PSA values in the
range of 2 to 10 ng/mL (n = 53 controls, 188 cases, AUC
54.3 %). There was no independent predictive power of
sarcosine for prediction of prostate cancer, controlling for
PSA, DRE, and the other risk factors for prostate cancer
(all p > 0.05, Table 2). Sarcosine similarly failed to be pre-
dictive of high- versus low-grade cancer (all p > 0.05).
Discussion
Several studies have postulated that sarcosine is causally
linked with the development and progression of prostate







or N (%) or N (%) P value
n = 251 n = 246
Age 64.8 (45.0–83.5) 64.1 (46.0–88.5) 0.80
Race 0.02
White 171 (68.1) 139 (56.5)
African American 34 (13.5) 38 (15.4)
Other 46 (18.3) 69 (28.0)
At least one previous
prostate biopsy
43 (17.1) 53 (21.5) 0.26
Abnormal Digital
Rectal Exam
7 (2.8) 70 (28.5) <0.001
Family history of
prostate cancer
28 (11.2) 62 (25.2) <0.001
Prostate-specific antigen
(ng/mL)
1.0 (0.1–8.4) 3.4 (0.0–93.8) <0.001
Sarcosine uM in 20 uL
serum (all samples)
16.2 (6.4–53.6) 15.8 (6.2–42.5) 0.40
Sarcosine
(only PSA 2–10 ng/mL)
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cancer. A large Norwegian study (n = 6000) concluded
that sarcosine should be used as an early detection
serum marker, but in contrast to other studies it found a
decreased association with risk of prostate cancer rather
than an increased one [3]. The reverse association could
be due to the fact that baseline sarcosine measurements
were used rather than those closer to the time of the bi-
opsy as used in this study (92.7 % within 1 year prior to
the biopsy, all the rest within 2.5 years prior). Two other
studies, one from the US (n = 2234) and one from Italy
(n = 602), found statistically significant increased associa-
tions between sarcosine and prostate cancer risk [4, 6].
The US study did not report an AUC for sarcosine, but
rather reported its odds ratio with the outcome of pros-
tate cancer to be 1.30 (95 % confidence interval 1.02 to
1.65). It noted that its inclusion in a clinical model did
not improve the AUC. The Italian study investigated the
AUC of sarcosine for all possible subsets of PSA, finding
its max value of 64 % for use in men with PSA < 4 ng/mL,
and its worst performance, which was no different from





























Fig. 1 Boxplots of sarcosine measurements among cancer cases (red) and controls (green) in the SABOR study for all cases and controls (left, 246
cases, 251 controls) and those with PSA in the 2 to 10 ng/mL range (right, 188 cases, 53 controls)
Table 2 Multivariable logistic regression model results for






Age 1.0 (0.9–1.1) 0.11
Race
African American 1.3 (0.6–3.0) 0.47
Other 1.2 (0.7–2.3) 0.49
At least one previous prostate biopsy 0.7 (0.3–1.3) 0.26
Abnormal Digital Rectal Exam 30.5 (11.8–92.2) <0.001
Family history of prostate cancer 3.5 (1.8–6.8) <0.001
Prostate-specific antigen (ng/mL)a 4.4 (3.3–5.9) <0.001
Sarcosine uM in 20uL seruma 1.1 (0.7–1.8) 0.64
aVariable was log2 transformed in the model
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random chance, for men either with PSA > 10 ng/mL or
between 4 and 10 ng/mL. The AUC remained marginally
but statistically significantly better than chance for use
among men with any value of PSA (AUC 57 %, 95 % CI
53 % to 61 %) as well as among men with PSA in the 2 to
10 ng/mL range (AUC 57 %, 95 % CI 52 % to 62 %).
The discordant findings of the SABOR prospectively-
collected cohort with findings of some previous studies
may have a number of explanations. First and foremost,
previous studies noting an association between serum
sarcosine and prostate cancer risk may be simply due to
chance. The tendency to false positives is increased be-
cause of the multiple comparisons typically evaluated for
sarcosine across different ranges of PSA; for example the
Italian study reported 5 AUCs [6]. The previous US study
did not report an AUC for sarcosine alone, but its inability
to budge the AUC based on clinical risk factors in the
study indicates the AUC may not have been statistically
significantly different from 50 % in accordance with this
study [4]. With the initial flurry of interest in this potential
biomarker, publication bias may have led to submission
and acceptance of only those studies that thereafter
confirmed this association, meaning that other negative
studies were not published. Other biases may also be
operational, including the fact that few previous evalua-
tions were conducted on prospectively-assembled co-
horts of patients at risk of prostate cancer, or that the
sarcosine measurements were taken too far in advance
of the biopsy, as was the case for the large Norwegian
study [3]. Unfortunately biomarker studies typically fail
to report the time interval between biomarker measure-
ment and the biopsy, which is particularly relevant for
the prostate cancer cases. SABOR followed a rigorous
protocol in which only cases were included where the
biomarker was measured within a window of 2.5 years
prior to the biopsy.
With its rigorous design, we believe this study elimi-
nates serum sarcosine for further investigation as an
early detection marker for prostate cancer. However,
sarcosine may have a role in urine. Four studies investi-
gating urine sarcosine for early detection all reported
AUCs in the upper 60s and lower 70s, all statistically sig-
nificantly better than chance in prediction [1, 7–9].
Urinary sarcosine seems to be more predictive of pros-
tate cancer and may be utilized along with PSA and
DRE in screening protocols.
Conclusions
Serum sarcosine, while exhibiting promising results for the
early detection of prostate cancer in in some prior studies,
had no value in this independent analysis of men undergo-
ing screening in San Antonio, Texas. Serum sarcosine
should not be pursued further as a marker for the early
detection of prostate cancer.
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